High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancer

Medientyp: E-Artikel
Titel: High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancer
Beteiligte: Göbel, Andy [Verfasser:in]; Rachner, Tilman Daniel [Verfasser:in]; Hoffmann, Oliver [Verfasser:in]; Klotz, Daniel Martin [Verfasser:in]; Kasimir-Bauer, Sabine [Verfasser:in]; Kimmig, Rainer [Verfasser:in]; Hofbauer, Lorenz [Verfasser:in]; Bittner, Ann-Kathrin [Verfasser:in]
Erschienen: June 2024
Erschienen in: Archives of gynecology and obstetrics ; 309(2024), 6 vom: Juni, Seite 2789-2798
Sprache: Englisch
DOI: 10.1007/s00404-024-07434-0
Identifikator:

Schlagwörter: LRG-1; Early breast cancer; Prognostic marker; Serum marker; Minimal residual disease; Disseminated tumor cells
Entstehung:
Anmerkungen: Online veröffentlicht am 28. Februar 2024
Beschreibung: Leucine-rich α-2 glycoprotein 1 (LRG-1) is a secreted glycoprotein that is mainly produced in the liver. Elevated levels of LRG-1 are found in a multitude of pathological conditions including eye diseases, diabetes, infections, autoimmune diseases, and cancer. In patients with early breast cancer (BC), high intratumoral LRG-1 protein expression levels are associated with reduced survival. In this study, we assessed serum levels of LRG-1 in patients with early BC and investigated its correlation with the presence of disseminated tumor cells (DTCs) in the bone marrow and survival outcomes.
Zugangsstatus: Freier Zugang

Nur in Feld suchen: